Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Clinical Trial of Motixafortide for Measurable Residual Disease (MRD) Sensitization in Acute Myeloid Leukemia (AML)

NCT07392970 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT07392970
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07392970 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Clinical Trial of Motixafortide for Measurable Residual Disease (MRD) Sensitization in Acute Myeloid Leukemia (AML)
Lead sponsor
Washington University School of Medicine
Phase
Phase 2
Overall status
Recruiting
Start date
July 23, 2026
Completion date
February 2, 2030
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, measurable residual disease